Protocol Ledger

NCT06511648 · Phase II · RECRUITING

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Interventional Phase II clinical trial protocol NCT06511648 sponsored by Spanish Oncology Genito-Urinary Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-07 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06511648
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06511648
Protocol FieldVerified Registry Value
NCT IdentifierNCT06511648
Consolidated Lead SponsorSpanish Oncology Genito-Urinary Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2023-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06511648
Hospital Research SiteLocationSite Profile
Institut Gustave RoussyVillejuif, FranceOpen Hospital Dossier ->
Hospital Clínic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario 12 de OctubreMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI